pembrolizumab
Merck
['gyn', 'peacocc', 'clear,trial', 'clear,result', 'pembro']
peacocc trial results shows very promising activity of pembrolizumab in clear cell gyne cancer with median pfs of 12.2 wks, pfs rate at 12 wks of 43.5% and orr of 25% #esmo22 
Medical oncologist - Drug development Department (DITEP) / Interception program for cancer prevention - Gustave Roussy Cancer Center 

Cooking aficionado =)